Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma

Iwaki, Takuya; Niimi, Aya; Kano, Masato; Kurokawa, Yoshiaki; Yoshizaki, Uran; Nozaki, Keina; Nomiya, Akira; Miyazaki, Hideyo; Kume, Haruki

doi:10.1002/iju5.12231

Cited by 7 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, there are several reports in which nivolumab and ipilimumab were initiated in patients with renal cell carcinoma on HD (6)(7)(8)(9)(10)(11). However, there are no such reports on other types of cancers, and this is the first report of a patient with NSCLC on HD receiving this regimen (Table ).…”

Section: Discussionmentioning

confidence: 93%

PD-L1-negative Non-small-cell Lung Cancer Treated with Nivolumab Plus Ipilimumab during Maintenance Hemodialysis Results in Rapid Initial Progression Followed by a Long-lasting Response

et al. 2024

View full text Add to dashboard Cite

Nivolumab plus ipilimumab is one of the first-line treatments for advanced non-small-cell lung cancer (NSCLC), but the safety and efficacy in patients on hemodialysis (HD) is unclear. We herein report a patient with NSCLC on HD in whom nivolumab and ipilimumab were initiated. We observed general deterioration and enlarged lesions, followed by a long-term response. The patient developed secondary hypoadrenocorticism, an immune-related adverse event that was easily controlled. Nivolumab plus ipilimumab can be used safely for patients with NSCLC on HD. Long-term effectiveness can be observed after initial progression, so we should carefully assess the response.

show abstract

Section: Discussionmentioning

confidence: 93%

PD-L1-negative Non-small-cell Lung Cancer Treated with Nivolumab Plus Ipilimumab during Maintenance Hemodialysis Results in Rapid Initial Progression Followed by a Long-lasting Response

et al. 2024

View full text Add to dashboard Cite

show abstract

“…However, there are few data regarding the efficacy and safety of combination therapies, such as Ave plus axitinib, for patients with ESRD who are undergoing hemodialysis, because all of the key clinical trials excluded such patients [1][2][3]. Several case reports have presented the outcomes associated with combination therapies [4][5][6][7], but there have been no previous case reports of the use of Ave plus axitinib (Table 1). Therefore, we retrospectively researched the efficacy and safety of the use of combination therapy in patients with ESRD undergoing hemodialysis.…”

Section: Discussionmentioning

confidence: 99%

Avelumab plus Axitinib for the Treatment of Patients with End-Stage Renal Disease Undergoing Dialysis: A Retrospective Case Series and Literature Review

et al. 2023

View full text Add to dashboard Cite

Combination therapies of an immune checkpoint inhibitor and a molecular targeted agent are widely accepted as an appropriate initial systemic therapy for metastatic renal cell carcinoma (RCC), but there is little published evidence regarding the efficacy of this approach in patients with end-stage renal disease (ESRD). Here, we report three patients who were undergoing hemodialysis for ESRD whose metastatic RCC was successfully treated using avelumab plus axitinib. The patients were a 67-year-old man with swollen lymph nodes, a 65-year-old man with pleural dissemination, and a 71-year-old man with lung nodules and an infra-diaphragmatic nodule. They were administered a combination of avelumab plus axitinib as their initial systemic therapy following definitive surgical therapy. The best response of three patients was graded as partial response. No severe adverse events were identified. This is the first report of the use of combination therapy consisting of avelumab plus axitinib in patients with ESRD undergoing hemodialysis. We found that this combination was useful in such patients.

show abstract

Approach to Special Populations with Advanced Renal Cell Carcinoma

Gulati,

Jiang

2023

Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma

View full text Add to dashboard Cite

Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma

Abstract: Abbreviations & Acronyms CT = computed tomography ESRD = end-stage renal disease ICI = immune checkpoint inhibitor irAE = immune-related adverse event mRCC = metastatic renal cell carcinoma RCC = renal cell carcinoma

Cited by 7 publications

References 17 publications

PD-L1-negative Non-small-cell Lung Cancer Treated with Nivolumab Plus Ipilimumab during Maintenance Hemodialysis Results in Rapid Initial Progression Followed by a Long-lasting Response

PD-L1-negative Non-small-cell Lung Cancer Treated with Nivolumab Plus Ipilimumab during Maintenance Hemodialysis Results in Rapid Initial Progression Followed by a Long-lasting Response

Avelumab plus Axitinib for the Treatment of Patients with End-Stage Renal Disease Undergoing Dialysis: A Retrospective Case Series and Literature Review

Approach to Special Populations with Advanced Renal Cell Carcinoma

Contact Info

Product

Resources

About